AMIOVERTAmiodarone vs. Implantable Defibrillator in Patients with Nonischemic Cardiomyopathy & Asymptomatic Non-sustained Ventricular Tachycardia. A clinical trial comparing the effect on mortality of amiodarone vs an implantable cardioverter-defibrillator (ICD) in patients with nonischemic dilated cardiomyopathy (NIDCM) and asymptomatic non-sustained ventricular tachcardia (NSVT).
Primary endpoints Mortality.
Conclusion AMIOVERT was stopped at the first interim analysis because the pre-specified stopping rule for futility was reached; data was extrapolated to 600 patients; p-value did not reach statistical significance; in patients with NIDCM, LVEF <35%, and asymptomatic NSVT, AMIOVERT suggests that total mortality at 4 years is the same with amiodarone or an ICD.